Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met its primary endpoint of non-inferiority of major adverse cardiovascular events (MACE) versus placebo in type 2 diabetes patients at high risk of cardiovascular events.
In the study of 3,183 participants, oral semglutide reduced the incidence of MACE by 21%, and reduced occurrence of cardiovascular death by 51%, but the former did not reach statistical significance and the latter.
